Clinical Trials · NCT06634927

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Enrollment
68
Start date
Sep 2024
Locations
1 site, China
Primary endpoint
AUC0-inf
View Semaglutide compound reference